Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | HMOX2 | P30519 | 1/20 | 1.00 |
| ▸ | CRYZ | Q08257 | 1/20 | 1.00 |
| ▸ | VAT1 | Q99536 | 1/20 | 1.00 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373530 | 1.00 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29379971 | 1.00 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL31658077 | 0.97 | KRAS (0.93) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18128690 | 0.97 | KRAS (0.93) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29765662 | 0.94 | KRAS (0.88) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16647182 | 0.94 | KRAS (0.88) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29766035 | 0.92 | KRAS (0.84) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16646915 | 0.92 | KRAS (0.84) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL18842314 | 0.91 | KRAS (0.83) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL21471922 | 0.90 | KRAS (0.82) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082648-A1 | COMPOSITIONS AND METHODS FOR ENHANCING KRAS INHIBITOR OR SHP2 INHIBITOR EFFICACY | NEW YORK UNIVERSITY (US) | 2025-03-13 | — | — | US | claimed |
| EP-4249000-A2 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND A KRASG12C INHIBITOR | Novartis AG (CH) | 2023-09-27 | — | — | EP | claimed |
| US-20230285498-A1 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE | 2023-09-14 | — | — | US | claimed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| US-20220152026-A1 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND A KRASG12C INHIBITOR | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | claimed |
| CN-113382774-A | Pharmaceutical combination comprising TNO155 and KRASG12C inhibitors | 诺华股份有限公司 | 2021-09-10 | — | — | CN | claimed |
| EP-3193851-B1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2020-10-21 | — | — | EP | claimed |
| EP-3055290-B1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2019-10-02 | — | — | EP | claimed |
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250082648-A1 | COMPOSITIONS AND METHODS FOR ENHANCING KRAS INHIBITOR OR SHP2 INHIBITOR EFFICACY | NEW YORK UNIVERSITY (US) | 2025-03-13 | — | — | US | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2024-11-14 | — | — | US | disclosed |
| US-20240376155-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | KRAS 1/4885EGFR 479/4885HMOX2 2652/4885 |
| US-20240374571-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | TP53, TEAD2, SERPINB1 | KRAS 7/4885EGFR 225/4885HMOX2 1722/4885 |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 235/4885HMOX2 4490/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885EGFR 180/4885HMOX2 4456/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KRAS 3/4885EGFR 14/4885HMOX2 2737/4885 |
| US-20220152026-A1 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND A KRASG12C INHIBITOR | KRAS, NRAS, TP53 | KRAS 1/4885EGFR 191/4885HMOX2 1902/4885 |
| US-20240376155-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL CANCERS | TP53, KRAS, VHL | KRAS 2/4885EGFR 16/4885HMOX2 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.